Novartis is a global healthcare company focused on pharmaceuticals and generics. Its core products include innovative medicines in areas such as oncology, cardiology, immunology, and neuroscience. The company operates through two main segments: Innovative Medicines and Sandoz, which provides generic pharmaceuticals. Major revenue sources stem from patented drugs and biosimilars, with a strong emphasis on research and development to drive growth in its product pipeline.
The investment profile of Novartis is more aligned with dividend investors due to its stable dividend yield of 4.1%. The company has a solid history of returning value to shareholders, making it suitable for those seeking income. However, its recent revenue decline suggests a cautious approach for growth investors. Overall, it may appeal to balanced investors looking for a mix of income and moderate growth potential.
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-06-27 | Hold | Buy | Strong fundamentals and positive momentum support growth potential. |
| 2026-06-19 | Buy | Hold | Weak momentum and high risk; cautious approach advised. |
| 2026-06-11 | Hold | Buy | Stable dividend, moderate growth, mixed momentum signals. |
| 2026-06-03 | Buy | Hold | Weak fundamentals and negative momentum raise concerns. |
| 2026-05-26 | Hold | Buy | Stable dividend, but mixed performance and fundamentals. |
| 2026-05-16 | Sell | Hold | Mixed performance; cautious outlook amid market pressures. |
| 2026-05-08 | — | Sell | Weak fundamentals and negative momentum raise concerns. |
| 2026-05-08 | Buy | Hold | Компания показывает стабильный дивидендный доход и положительный рост за последние 120 дней, однако недавние падения цен и снижение выручки вызывают опасения. |
| 2026-03-27 | Hold | Buy | Компания показывает стабильные результаты с хорошей дивидендной доходностью, но недавнее снижение выручки и колебания цен могут указывать на неопределенность в краткосрочной перспективе. |
| 2026-03-20 | Buy | Hold | Компания показывает стабильный рост за последние 120 дней, однако недавние падения цены и снижение выручки могут указывать на временные трудности. Дивидендная доходность в 4.06% делает акцию привлекательной для долгосроч |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-03-26 | Morgan Stanley | Target Raised | 143 → 170 | 149.7 |
| 2025-12-10 | HSBC | Target Raised | 106 → 112 | 131.01 |
| 2025-12-03 | Morgan Stanley | Target Raised | 136 → 143 | 132.28 |
| 2025-10-29 | CFRA | Target Raised | — → 126 | 123.33 |
